Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

NCT06712316 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06712316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
Lead sponsor
BioNTech SE
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 7, 2025
Completion date
December 31, 2031
Enrollment
1,580 (estimated)
Sites
365

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer